Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 50,000 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 50,000 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $119.00, for a total value of $5,950,000.00. Following the transaction, the chief executive officer directly owned 666,568 shares in the company, valued at approximately $79,321,592. The trade was a 6.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Nello Mainolfi also recently made the following trade(s):

• On Wednesday, July 1st, Nello Mainolfi sold 80,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $115.29, for a total transaction of $9,223,200.00.
• On Wednesday, April 29th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $81.18, for a total transaction of $2,435,400.00.

Kymera Therapeutics Stock Performance

KYMR traded up $4.48 during trading on Tuesday, reaching $119.24. 827,668 shares of the company traded hands, compared to its average volume of 1,247,150. Kymera Therapeutics, Inc. has a 12-month low of $36.65 and a 12-month high of $130.05. The firm has a fifty day simple moving average of $87.91 and a 200 day simple moving average of $83.32. The company has a market cap of $9.81 billion, a P/E ratio of -33.40 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. The firm had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business’s quarterly revenue was up 55.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.82) EPS. As a group, sell-side analysts expect that Kymera Therapeutics, Inc. will post -3.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC raised its holdings in Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after acquiring an additional 424 shares during the last quarter. Larson Financial Group LLC grew its position in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares during the period. Osaic Holdings Inc. grew its position in shares of Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after purchasing an additional 1,083 shares during the period. GAMMA Investing LLC increased its stake in Kymera Therapeutics by 27.5% in the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after purchasing an additional 98 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Kymera Therapeutics in the fourth quarter valued at $63,000.

Analyst Ratings Changes

KYMR has been the topic of several research analyst reports. Morgan Stanley reiterated an “overweight” rating and issued a $119.00 target price on shares of Kymera Therapeutics in a research report on Thursday, April 30th. Loop Capital set a $97.00 price target on shares of Kymera Therapeutics in a research note on Monday, June 8th. Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Canaccord Genuity Group increased their price objective on Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a research report on Friday, June 26th. Finally, Bank of America lifted their target price on Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $121.41.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.